• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Vibration may have role in treating neonatal opioid withdrawal syndrome

byMolly MunsellandAlex Gipsman, MD
June 1, 2023
in Chronic Disease, Neurology, Pediatrics, Psychiatry, Public Health
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In a randomized controlled trial assessing the addition of a vibrating crib to standard therapy for opioid exposure in neonates, the use of vibration was not associated with a significant reduction in the number of infants who went on to require morphine treatment. 

2. A significant dose-response effect of vibration therapy was observed, with each hour per day of vibration associated with a 12% reduction in the odds of requiring morphine treatment.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Neonatal opioid withdrawal syndrome (NOWS) due to prenatal exposure to opioids is associated with a variety of neurological and gastrointestinal symptoms. NOWS is often managed with morphine, which can negatively impact development and typically requires admission to a neonatal intensive care unit (NICU). Past studies have suggested that mechanical stimulation, particularly low-level stochastic, or random, vibration, may help prevent or treat NOWS. This randomized trial aimed to assess a vibrating crib in avoiding the need for opioid therapy in infants exposed to opioids. Among a total of 181 infants randomized to receive standard therapy with or without the addition of an oscillating crib mattress, 33.1% required NICU transfer and morphine treatment. This rate did not significantly differ for infants receiving the intervention. However, the duration of vibration therapy was significantly associated with lower odds of requiring morphine — 12% per hour per day of vibration. Among the subgroup completing NOWS treatment within 3 weeks, though not among the entire study population, infants receiving vibration required significantly less morphine and for a shorter duration. This trial provides evidence of a real, though modest, effect of stochastic vibration in improving outcomes for neonates exposed to opioids. A new addition to the bundle of nonpharmacologic treatments used to minimize morphine use, including holding by caregivers, would be welcome, but the improvements shown here must be balanced with the difficulty of broadly implementing the custom vibrating crib setup used in this study.

Click to read the study in JAMA Pediatrics

Relevant Reading: Neonatal opioid withdrawal syndrome

RELATED REPORTS

Characterization of meconium-related obstruction and outcomes in term and preterm infants

Naldemedine may be effective for opioid-induced constipation in patients with cancer

Emergency departments likely overprescribing opioids for acute pain

In-Depth [randomized controlled trial]: Neonates born at or after 37 weeks gestation after prenatal exposure to opioids at two tertiary centers between 2017 and 2020 were included. Opioid exposure was confirmed based on maternal medical records or either meconium or neonatal urine toxicology. Infants with significant congenital anomalies or severe birth complications were excluded. Infants in the treatment group had their crib mattresses replaced with customized mattresses programmed to vibrate stochastically for 3 hours on then 3 hours off, whether or not the infant was in the crib. The need for NICU transfer and treatment using morphine was determined based on 3 consecutive modified Finnegan scores of 8 or higher or 2 of 12 or higher. Intention-to-treat analysis was used. Analysis using a regression-based model of the effect of vibration duration on morphine treatment indicated that for infants receiving an average of 6 hours per day of vibration therapy, the odds of morphine therapy were reduced by 50%. Among the subgroup of infants treated in less than 3 weeks, those treated with vibration received morphine for 26% lower duration [95% confidence interval (CI) -0.47 to -0.04) and 1.76 mg/kg less morphine (95% CI -3.02 to -0.50).

Image: PD

©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: neonatal abstinence syndromeneonatal opioid withdrawalneonatologyNICUopioids
Previous Post

Wellness Check: Mental Health

Next Post

The 2 Minute Medicine Podcast Episode 16

RelatedReports

Poverty, preterm birth demonstrate additive effect on cognition
Career Development

Characterization of meconium-related obstruction and outcomes in term and preterm infants

February 21, 2025
Quick Take: The clinical effectiveness of sertraline in primary care and the role of depression severity and duration (PANDA): a pragmatic, double-blind, placebo-controlled randomized trial
Chronic Disease

Naldemedine may be effective for opioid-induced constipation in patients with cancer

September 17, 2024
Parental nonmedical prescription opioid use linked to adolescent use
Chronic Disease

Emergency departments likely overprescribing opioids for acute pain

July 27, 2024
Racial, ethnic differences in outcomes of extremely preterm infants decreasing but persistent
Emergency

Comparison of different types of ultrasound probes for lung ultrasound in neonates

July 12, 2024
Next Post
The 2 Minute Medicine Podcast Episode 15

The 2 Minute Medicine Podcast Episode 16

Oophorectomy associated with reduced cancer risk and all-cause mortality for BRCA1/2 patients

Genomic screening for hereditary conditions is cost-effective in young adults

#VisualAbstract: Sparsentan superior to irbesartan for reduction of proteinuria in patients with IgA nephropathy

#VisualAbstract: Sparsentan superior to irbesartan for reduction of proteinuria in patients with IgA nephropathy

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Transcatheter closure of patent ductus arteriosus demonstrates similar outcomes compared to surgical repair
  • #VisualAbstract: Encorafenib, Cetuximab, and mFOLFOX6 Improves Survival in BRAF-Mutated Colorectal Cancer
  • Use of psychiatric medications may be associated with a higher risk of amyotrophic lateral sclerosis
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.